ArticleJournal of neuro-oncology2012
Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.
Article in Journal of neuro-oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 6 syntheses or guidelines pooled it, 195 citations in OpenAlex.
- Systemic therapy in the treatment of recurrent or refractory intracranial meningiomas: A systematic review and individual patient data meta-analysis.Neurosurgical review · 2026Pooled it
- Benchmarking the efficacy of salvage systemic therapies for recurrent meningioma: A RANO group systematic review and meta-analysis to guide clinical trial design.Neuro-oncology · 2025Pooled it
- Application of bevacizumab in the management of meningiomas: a systematic review and meta-analysis.Neurosurgical review · 2024Pooled it
- The role of bevacizumab for treatment-refractory intracranial meningiomas: a single institution's experience and a systematic review of the literature.Acta neurochirurgica · 2022Pooled it
- EANO guideline on the diagnosis and management of meningiomas.Neuro-oncology · 2021Guideline
- Apatinib in recurrent anaplastic meningioma: a retrospective case series and systematic literature review.Cancer biology & therapy · 2020Pooled it
- Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).Neuro-oncology · 2022Trial
- Role of 3D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study.Neuro-oncology · 2021Trial
- A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma.Journal of neuro-oncology · 2016Trial
- Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Trial
- Intratumoral and peritumoral post-irradiation changes, but not viable tumor tissue, may respond to bevacizumab in previously irradiated meningiomas.Radiation oncology (London, England) · 2015Trial
- Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.Neuro-oncology · 2015Trial
- A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas.Journal of neuro-oncology · 2014Trial
- Temporally-Modulated Pulsed Radiation Therapy for Large-Volume Reirradiation of Recurrent Meningioma.Advances in radiation oncology · 2026Article
- Targeted and Personalized Therapy for Difficult Benign Brain Tumors: A Review.Journal of personalized medicine · 2026Review
- Review
- The tumour immune microenvironment is enriched but suppressed in vestibular schwannoma compared to meningioma: therapeutic implications for NF2-related schwannomatosis.Acta neuropathologica communications · 2025Article
- SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factors.European journal of nuclear medicine and molecular imaging · 2025Article
- A Retrospective Study on Prognostic Factors and Systemic Treatments of Refractory Meningiomas.Current oncology (Toronto, Ont.) · 2025Article
- Peptide radionuclide radiation therapy with Lutathera in multirecurrent nonanaplastic meningiomas: antitumoral activity study by growth rate analysis.Journal of neuro-oncology · 2024Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
Intracranial meningiomas are often indolent tumors which typically grow over years to decades. Nonetheless, meningiomas that progress after maximum safe resection and radiation therapy pose a significant therapeutic challenge and effective therapies have yet to be identified. Preclinical studies implicate angiogenesis in the pathophysiology of more aggressive meningiomas, suggesting that anti-angiogenic therapies may be of utility in this setting. We performed a retrospective review of fourteen patients with recurrent meningioma treated at Duke University Medical Center with bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor, administered either alone or in combination with chemotherapy. Most patients were heavily pre-treated. Progression-free survival at 6 months was 86 % and was comparable regardless of meningioma grade and whether bevacizumab was administered as monotherapy or in combination with chemotherapy. Most toxicities were mild however single patients developed CNS hemorrhage (grade 1) and intestinal perforation (grade 4), respectively. Bevacizumab can be administered safely to patients with meningioma and appears to be associated with encouraging anti-tumor effect when administered as either a single agent or in combination with chemotherapy. Phase II trials investigating bevacizumab in patients with progressive/recurrent meningioma are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.